Zepbound dosing schedule: what the FDA label says

The Zepbound dose ladder at a glance

Zepbound (tirzepatide) is FDA approved for chronic weight management and for moderate to severe obstructive sleep apnea (OSA) in adults with obesity (FDA, Nov 8, 2023) (FDA, Dec 20, 2024). Its label uses one escalation ladder for every indication. Titration means raising the dose in steps, and the label sets a minimum time on each step.

The “earliest week” column assumes each step lasts exactly 4 weeks, the label’s minimum. The label allows longer steps. It says to “consider treatment response and tolerability when selecting the maintenance dosage” (DailyMed, Aug 28, 2026). Not everyone climbs to 15 mg. A prescriber may stop at 5 mg or 10 mg.

Week-by-week schedule from a sample start date

The table below lays the ladder onto calendar dates using a sample first dose on Monday, Jan 5, 2026. It is an illustration of the label’s minimum timing, not a plan for any person.

The chart shows the same steps with a modeled amount of drug in the body. The model is a one-compartment estimate using a 5-day half-life. It reports a relative amount, not a blood level. See the methodology for details.

• Weekly dose (published steps)
• Modeled amount (mg-eq)
• Stable window

To shift the start date, hold a step longer or stop at a lower maintenance dose, use the tirzepatide titration tool. The tirzepatide plotter charts the modeled amount for any weekly schedule. The full-ladder dataset is on the label 15 mg protocol page.

Maintenance doses by indication

The label separates the escalation path from the maintenance dose. Maintenance is the dose a person stays on.

Two label sentences matter for anyone reading this table. First, “if patients do not tolerate a maintenance dosage, consider a lower maintenance dosage” (DailyMed, Aug 28, 2026). Second, 7.5 mg and 12.5 mg are escalation steps that the label does not list as maintenance doses. Talk to your prescriber before changing a dose.

The label’s Study 1 results show how outcomes differed across the three weight maintenance doses. In SURMOUNT-1 (Study 1 in the label, 2,539 adults without diabetes), mean weight change at week 72 was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, versus −3.1% with placebo. These are treatment-regimen estimand results, which count everyone randomized regardless of whether they stopped treatment (N Engl J Med, Jul 21, 2022). Discontinuation because of adverse events was 4.3%, 7.1% and 6.2% at 5, 10 and 15 mg, versus 2.6% with placebo (N Engl J Med, Jul 21, 2022).

Why the label sets at least 4 weeks per step

The label says to follow the escalation schedule “to reduce the risk of gastrointestinal adverse reactions” (DailyMed, Aug 28, 2026). In the label’s pooled table, nausea, diarrhea and vomiting were all far more common than with placebo, and diarrhea and vomiting rose with each maintenance dose.

Pharmacokinetics also explain the 4-week rhythm. The label reports steady-state concentrations after 4 weeks of once-weekly dosing and an elimination half-life of about 5 to 6 days (DailyMed, Aug 28, 2026). Steady state is the point where the amount absorbed each week balances the amount cleared. Our model, using a 5-day half-life, puts the weekly accumulation ratio at about 1.61. More side-effect detail is on the tirzepatide side effects guide.

Missed doses and changing your dosing day

The missed-dose rule uses a 4-day window (DailyMed, Aug 28, 2026).

A worked example: if the usual dose is Monday at 8 a.m., the 96-hour window closes Friday at 8 a.m. After that, the label says to skip that week’s dose and resume the following Monday. If anything about a missed dose is unclear, ask your pharmacist or prescriber.

Switching between Zepbound presentations

Zepbound now comes in four presentations. The dose in milligrams is the same across them, but the volume per dose is not (DailyMed, Aug 28, 2026).

What the label says about a switch (DailyMed, Aug 28, 2026):

• Patients and caregivers should be told which presentation they will receive and trained for that specific presentation.
• If the prescribed presentation changes, they should receive training again and read the Instructions for Use for the new presentation.
• The KwikPen is not recommended for self-administration by people who are visually impaired.
• People using vials should use a syringe suited to the dose, for example a 1 mL syringe that can measure 0.5 mL or 0.6 mL, and a new syringe and needle for each dose.

Because a multi-dose vial dose is 0.6 mL and a single-dose vial dose is 0.5 mL, the volume drawn up changes when you switch even though the mg dose does not. Your pharmacist can walk through the new device. Storage limits differ too; the tirzepatide storage tool lists them by presentation, and the injection sites guide covers what the label says about where doses go.

What the label says about the 15 mg ceiling

The label sets 15 mg once weekly as “the maximum dosage of ZEPBOUND for all indications” (DailyMed, Aug 28, 2026). It lists no dose above 15 mg, and the escalation ladder ends there.

The label also limits combinations. It says coadministration with other tirzepatide-containing products, such as Mounjaro, or with any GLP-1 receptor agonist is not recommended (DailyMed, Aug 28, 2026). Compounded tirzepatide is not FDA approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed (FDA, Oct 1, 2026). Compounded products are not interchangeable with Zepbound.

The type 2 diabetes brand of tirzepatide uses a similar ladder with different rules; see the Mounjaro dosing schedule. For cost by dose, see the Zepbound savings card guide. The tirzepatide hub gathers the label facts for both brands. Any change to your dose or schedule is a decision to make with your prescriber.